Published in Sci Rep on January 01, 2013
CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol (2014) 9.18
CRISPR-Cas systems: Prokaryotes upgrade to adaptive immunity. Mol Cell (2014) 2.87
RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci U S A (2014) 2.32
CRISPR-based technologies: prokaryotic defense weapons repurposed. Trends Genet (2014) 1.60
The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. Mol Ther Nucleic Acids (2014) 1.46
Nuclear landscape of HIV-1 infection and integration. Nat Rev Microbiol (2016) 1.41
Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems. MBio (2014) 1.32
Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology (2014) 1.29
High-efficiency targeted editing of large viral genomes by RNA-guided nucleases. PLoS Pathog (2014) 1.13
RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. Proc Natl Acad Sci U S A (2014) 1.10
Newer gene editing technologies toward HIV gene therapy. Viruses (2013) 1.07
The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. Retrovirology (2015) 1.06
CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape. Mol Ther (2016) 1.06
A high excision potential of TALENs for integrated DNA of HIV-based lentiviral vector. PLoS One (2015) 1.01
Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy. Antiviral Res (2015) 0.97
CRISPR-Cas: an efficient tool for genome engineering of virulent bacteriophages. Nucleic Acids Res (2014) 0.96
Adenoviral vector delivery of RNA-guided CRISPR/Cas9 nuclease complexes induces targeted mutagenesis in a diverse array of human cells. Sci Rep (2014) 0.96
Core Concept: CRISPR gene editing. Proc Natl Acad Sci U S A (2015) 0.96
Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication. World J Gastroenterol (2015) 0.94
Epigenome engineering in cancer: fairytale or a realistic path to the clinic? Front Oncol (2015) 0.92
Personalized therapeutic strategies for patients with retinitis pigmentosa. Expert Opin Biol Ther (2015) 0.92
Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity. Nat Biotechnol (2016) 0.90
CRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC Infection. PLoS One (2015) 0.90
Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment. Virology (2015) 0.90
CRISPR-mediated Activation of Latent HIV-1 Expression. Mol Ther (2015) 0.88
Genome editing strategies: potential tools for eradicating HIV-1/AIDS. J Neurovirol (2015) 0.87
Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system. J Orthop Res (2014) 0.86
The CRISPR/Cas9 genome editing methodology as a weapon against human viruses. Discov Med (2015) 0.86
DNA cleavage enzymes for treatment of persistent viral infections: recent advances and the pathway forward. Virology (2014) 0.86
HIV Excision Utilizing CRISPR/Cas9 Technology: Attacking the Proviral Quasispecies in Reservoirs to Achieve a Cure. MOJ Immunol (2014) 0.85
Inhibition of HSV-1 Replication by Gene Editing Strategy. Sci Rep (2016) 0.85
"Off-Spotter": very fast and exhaustive enumeration of genomic lookalikes for designing CRISPR/Cas guide RNAs. Biol Direct (2015) 0.84
Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study. Gene Ther (2016) 0.84
Applications of CRISPR-Cas9 mediated genome engineering. Mil Med Res (2015) 0.84
HIV-1 functional cure: will the dream come true? BMC Med (2015) 0.84
CRISPR-Cas9-based knockout of the prion protein and its effect on the proteome. PLoS One (2014) 0.83
Damaging the Integrated HIV Proviral DNA with TALENs. PLoS One (2015) 0.83
The therapeutic application of CRISPR/Cas9 technologies for HIV. Expert Opin Biol Ther (2015) 0.83
Towards a new era in medicine: therapeutic genome editing. Genome Biol (2015) 0.83
A Biophysical Model of CRISPR/Cas9 Activity for Rational Design of Genome Editing and Gene Regulation. PLoS Comput Biol (2016) 0.83
CRISPR/Cas9: a double-edged sword when used to combat HIV infection. Retrovirology (2016) 0.82
Functional screening of guide RNAs targeting the regulatory and structural HIV-1 viral genome for a cure of AIDS. AIDS (2016) 0.82
Engineering T Cells to Functionally Cure HIV-1 Infection. Mol Ther (2015) 0.81
Designed transcription activator-like effector proteins efficiently induced the expression of latent HIV-1 in latently infected cells. AIDS Res Hum Retroviruses (2015) 0.81
RNA interference approaches for treatment of HIV-1 infection. Genome Med (2015) 0.81
Gene therapy strategies for HIV/AIDS: preclinical modeling in humanized mice. Viruses (2013) 0.80
CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections. PLoS Pathog (2016) 0.80
A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape. Sci Rep (2017) 0.80
HIV-1 Latency and Eradication: Past, Present and Future. Curr HIV Res (2016) 0.80
Lentivirus pre-packed with Cas9 protein for safer gene editing. Gene Ther (2016) 0.80
Cell and gene therapy strategies to eradicate HIV reservoirs. Curr Opin HIV AIDS (2016) 0.80
Neurogenethics: An emerging discipline at the intersection of ethics, neuroscience, and genomics. Appl Transl Genom (2015) 0.79
The clinical applications of genome editing in HIV. Blood (2016) 0.79
In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models. Mol Ther (2017) 0.79
Host Double Strand Break Repair Generates HIV-1 Strains Resistant to CRISPR/Cas9. Sci Rep (2016) 0.79
Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions. Expert Rev Anti Infect Ther (2014) 0.79
Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense. Trends Microbiol (2016) 0.79
A new world order: tailored gene targeting and regulation using CRISPR. Mol Ther (2014) 0.79
Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeutic. Methods (2015) 0.78
Synthetic biology for therapeutic applications. Mol Pharm (2014) 0.78
In Vitro and In Vivo Synergistic Therapeutic Effect of Cisplatin with Human Papillomavirus16 E6/E7 CRISPR/Cas9 on Cervical Cancer Cell Line. Transl Oncol (2016) 0.78
Therapy of HIV Infection: Current Approaches and Prospects. Acta Naturae (2017) 0.78
Progress and prospects of engineered sequence-specific DNA modulating technologies for the management of liver diseases. World J Hepatol (2015) 0.77
CRISPR/Cas9-Mediated Immunity to Geminiviruses: Differential Interference and Evasion. Sci Rep (2016) 0.77
Targeting the latent reservoir to achieve functional HIV cure. F1000Res (2016) 0.77
Modulation of Gene Expression by Polymer Nanocapsule Delivery of DNA Cassettes Encoding Small RNAs. PLoS One (2015) 0.77
Reactivation of Latent HIV-1 Expression by Engineered TALE Transcription Factors. PLoS One (2016) 0.77
Recombinant Pseudorabies Virus (PRV) Expressing Firefly Luciferase Effectively Screened for CRISPR/Cas9 Single Guide RNAs and Antiviral Compounds. Viruses (2016) 0.77
Stem cell-based therapies for HIV/AIDS. Adv Drug Deliv Rev (2016) 0.77
Neuroprotective therapies in glaucoma: II. Genetic nanotechnology tools. Front Neurosci (2015) 0.77
An Effective Molecular Target Site in Hepatitis B Virus S Gene for Cas9 Cleavage and Mutational Inactivation. Int J Biol Sci (2016) 0.77
Minimizing off-Target Mutagenesis Risks Caused by Programmable Nucleases. Int J Mol Sci (2015) 0.77
CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer: a personalized molecular surgical therapy. EMBO Mol Med (2016) 0.76
Gene Editing for Treatment of Neurological Infections. Neurotherapeutics (2016) 0.76
Application of gene-editing technologies to HIV-1. Curr Opin HIV AIDS (2015) 0.76
The variances of Sp1 and NF-κB elements correlate with the greater capacity of Chinese HIV-1 B'-LTR for driving gene expression. Sci Rep (2016) 0.76
Genome-Edited T Cell Therapies. Curr Stem Cell Rep (2017) 0.76
Cell-based gene therapy against HIV. Gene Ther (2015) 0.75
Perspectives of Genome-Editing Technologies for HIV Therapy. Curr HIV Res (2016) 0.75
Reprogramming MHC specificity by CRISPR-Cas9-assisted cassette exchange. Sci Rep (2017) 0.75
Experimental Approaches for Eliminating Latent HIV. For Immunopathol Dis Therap (2015) 0.75
CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles. Mol Ther Nucleic Acids (2016) 0.75
The big bang of genome editing technology: development and application of the CRISPR/Cas9 system in disease animal models. Dongwuxue Yanjiu (2016) 0.75
Gene Editing Approaches against Viral Infections and Strategy to Prevent Occurrence of Viral Escape. PLoS Pathog (2016) 0.75
Stem cell, CRISPR and HIV. Cell Cycle (2015) 0.75
Negative Feedback Regulation of HIV-1 by Gene Editing Strategy. Sci Rep (2016) 0.75
Transgenic Clustered Regularly Interspaced Short Palindromic Repeat/Cas9-Mediated Viral Gene Targeting for Antiviral Therapy of Bombyx mori Nucleopolyhedrovirus. J Virol (2017) 0.75
CRISPR-Mediated Epigenome Editing. Yale J Biol Med (2016) 0.75
Antiviral Defenses in Plants through Genome Editing. Front Microbiol (2017) 0.75
Clinical Applications of Genome Editing to HIV Cure. AIDS Patient Care STDS (2016) 0.75
How to Define the Latent Reservoir: Tools of the Trade. Curr HIV/AIDS Rep (2016) 0.75
Modeling Viral Infectious Diseases and Development of Antiviral Therapies Using Human Induced Pluripotent Stem Cell-Derived Systems. Viruses (2015) 0.75
ge-CRISPR - An integrated pipeline for the prediction and analysis of sgRNAs genome editing efficiency for CRISPR/Cas system. Sci Rep (2016) 0.75
T-cell therapies for HIV: Preclinical successes and current clinical strategies. Cytotherapy (2016) 0.75
HIV Diagnosis and Treatment through Advanced Technologies. Front Public Health (2017) 0.75
Achieving HIV-1 Control through RNA-Directed Gene Regulation. Genes (Basel) (2016) 0.75
A stable but reversible integrated surrogate reporter for assaying CRISPR/Cas9-stimulated homology-directed repair. J Biol Chem (2017) 0.75
Novel AIDS therapies based on gene editing. Cell Mol Life Sci (2017) 0.75
Inhibition of JCPyV infection mediated by targeted viral genome editing using CRISPR/Cas9. Sci Rep (2016) 0.75
Mutant Cas9-transcriptional activator activates HIV-1 in U1 cells in the presence and absence of LTR-specific guide RNAs. Matters (Zur) (2017) 0.75
Multiplex genome engineering using CRISPR/Cas systems. Science (2013) 55.53
RNA-guided human genome engineering via Cas9. Science (2013) 48.29
Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature (2005) 19.15
RNA-guided genetic silencing systems in bacteria and archaea. Nature (2012) 17.12
Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci U S A (2012) 16.48
Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol (2013) 14.28
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol (2013) 11.58
A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action. Biol Direct (2006) 11.31
Heritable gene targeting in zebrafish using customized TALENs. Nat Biotechnol (2011) 8.34
Development of a self-inactivating lentivirus vector. J Virol (1998) 6.60
De novo-engineered transcription activator-like effector (TALE) hybrid nuclease with novel DNA binding specificity creates double-strand breaks. Proc Natl Acad Sci U S A (2011) 6.12
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J (2003) 6.11
Structures of the RNA-guided surveillance complex from a bacterial immune system. Nature (2011) 4.92
The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J (2001) 3.80
The discovery of zinc fingers and their applications in gene regulation and genome manipulation. Annu Rev Biochem (2010) 3.75
Efficient and specific modifications of the Drosophila genome by means of an easy TALEN strategy. J Genet Genomics (2012) 2.98
HIV latency. Cold Spring Harb Perspect Med (2011) 2.90
Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity (2012) 2.56
Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic Acids Res (2012) 2.14
Transcriptional and posttranscriptional regulation of HIV-1 gene expression. Cold Spring Harb Perspect Med (2012) 1.88
HIV DNA integration. Cold Spring Harb Perspect Med (2012) 1.73
The knockout rat pack. Nat Med (2010) 1.44
Specific HIV-1 TAR RNA loop sequence and functional groups are required for human cyclin T1-Tat-TAR ternary complex formation. Biochemistry (2002) 1.21
Quantitative analysis of human immunodeficiency virus type 1 DNA dynamics by real-time PCR: integration efficiency in stimulated and unstimulated peripheral blood mononuclear cells. Virus Genes (2003) 1.17
Plasma membrane-targeted Raf kinase activates NF-kappaB and human immunodeficiency virus type 1 replication in T lymphocytes. J Virol (1998) 1.10
Integrase-independent HIV-1 infection is augmented under conditions of DNA damage and produces a viral reservoir. Virology (2012) 0.94
Genetic and functional characterization of the LTR of HIV-1 subtypes A and C circulating in India. AIDS Res Hum Retroviruses (2007) 0.86
The importance of and a method for including transfection efficiency into real-time PCR data analyses. Biotechnol Bioeng (2008) 0.86
NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood (2002) 7.78
Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol (2004) 1.92
Antimicrobial peptide LL-37 produced by HSV-2-infected keratinocytes enhances HIV infection of Langerhans cells. Cell Host Microbe (2013) 1.56
Oral administration of the CCR5 inhibitor, maraviroc, blocks HIV ex vivo infection of Langerhans cells within the epithelium. J Invest Dermatol (2013) 1.44
Modulation of human immunodeficiency virus type 1 infectivity through incorporation of tetraspanin proteins. J Virol (2007) 1.38
Host factor SAMHD1 restricts DNA viruses in non-dividing myeloid cells. PLoS Pathog (2013) 1.37
Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction and susceptibility. J Virol (2010) 1.37
Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood (2005) 1.29
Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice. J Virol (2010) 1.22
No association of xenotropic murine leukemia virus-related virus with prostate cancer or chronic fatigue syndrome in Japan. Retrovirology (2011) 1.22
Quantitative analysis of human immunodeficiency virus type 1 DNA dynamics by real-time PCR: integration efficiency in stimulated and unstimulated peripheral blood mononuclear cells. Virus Genes (2003) 1.17
Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/gammac(null) mice: suppression by an inhibitor against NF-kappaB. J Virol (2003) 1.14
Vpu augments the initial burst phase of HIV-1 propagation and downregulates BST2 and CD4 in humanized mice. J Virol (2012) 1.14
HIV-1 Vpr induces TLR4/MyD88-mediated IL-6 production and reactivates viral production from latency. J Leukoc Biol (2010) 1.13
Selective infection of CD4+ effector memory T lymphocytes leads to preferential depletion of memory T lymphocytes in R5 HIV-1-infected humanized NOD/SCID/IL-2Rgammanull mice. Virology (2009) 1.11
A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice. Blood (2011) 1.10
Comparative study on the effect of human BST-2/Tetherin on HIV-1 release in cells of various species. Retrovirology (2009) 1.08
Role of Nup98 in nuclear entry of human immunodeficiency virus type 1 cDNA. Microbes Infect (2004) 1.06
Solution RNA structures of the HIV-1 dimerization initiation site in the kissing-loop and extended-duplex dimers. J Biochem (2005) 1.05
HIV-1 viral infectivity factor interacts with TP53 to induce G2 cell cycle arrest and positively regulate viral replication. Proc Natl Acad Sci U S A (2010) 1.03
Human immunodeficiency virus type 1 Vpr inhibits axonal outgrowth through induction of mitochondrial dysfunction. J Virol (2007) 1.02
A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A (2003) 1.00
Vpr in plasma of HIV type 1-positive patients is correlated with the HIV type 1 RNA titers. AIDS Res Hum Retroviruses (2007) 0.99
A CD63 mutant inhibits T-cell tropic human immunodeficiency virus type 1 entry by disrupting CXCR4 trafficking to the plasma membrane. Traffic (2008) 0.98
MDM2 is a novel E3 ligase for HIV-1 Vif. Retrovirology (2009) 0.98
Dynamics of memory and naïve CD8+ T lymphocytes in humanized NOD/SCID/IL-2Rgammanull mice infected with CCR5-tropic HIV-1. Vaccine (2010) 0.97
Significant virus replication in Langerhans cells following application of HIV to abraded skin: relevance to occupational transmission of HIV. J Immunol (2008) 0.95
Identifying viral parameters from in vitro cell cultures. Front Microbiol (2012) 0.95
A lentiviral cDNA library employing lambda recombination used to clone an inhibitor of human immunodeficiency virus type 1-induced cell death. J Virol (2004) 0.94
Integrase-independent HIV-1 infection is augmented under conditions of DNA damage and produces a viral reservoir. Virology (2012) 0.94
Tumor necrosis factor-related apoptosis-inducing ligand induces neuronal death in a murine model of HIV central nervous system infection. Proc Natl Acad Sci U S A (2003) 0.94
The mouse is out of the bag: insights and perspectives on HIV-1-infected humanized mouse models. Exp Biol Med (Maywood) (2011) 0.93
N-linked glycan-dependent interaction of CD63 with CXCR4 at the Golgi apparatus induces downregulation of CXCR4. Microbiol Immunol (2009) 0.93
De novo human T-cell leukemia virus type 1 infection of human lymphocytes in NOD-SCID, common gamma-chain knockout mice. J Virol (2006) 0.92
APOBEC1-mediated editing and attenuation of herpes simplex virus 1 DNA indicate that neurons have an antiviral role during herpes simplex encephalitis. J Virol (2011) 0.91
HIV-1 Vpr accelerates viral replication during acute infection by exploitation of proliferating CD4+ T cells in vivo. PLoS Pathog (2013) 0.91
Quantification of deaminase activity-dependent and -independent restriction of HIV-1 replication mediated by APOBEC3F and APOBEC3G through experimental-mathematical investigation. J Virol (2014) 0.89
Vpu and BST2: Still Not There Yet? Front Microbiol (2012) 0.87
Identification of the P-TEFb complex-interacting domain of Brd4 as an inhibitor of HIV-1 replication by functional cDNA library screening in MT-4 cells. FEBS Lett (2008) 0.87
Separate elements are required for ligand-dependent and -independent internalization of metastatic potentiator CXCR4. Cancer Sci (2007) 0.87
Primary target cells of herpes simplex virus type 1 in the hippocampus. Microbes Infect (2008) 0.85
Functional disruption of the moloney murine leukemia virus preintegration complex by vaccinia-related kinases. J Biol Chem (2010) 0.85
Quantification of the dynamics of enterovirus 71 infection by experimental-mathematical investigation. J Virol (2012) 0.85
Death ligand-mediated apoptosis in HIV infection. Rev Med Virol (2005) 0.84
A novel protective MHC-I haplotype not associated with dominant Gag-specific CD8+ T-cell responses in SIVmac239 infection of Burmese rhesus macaques. PLoS One (2013) 0.84
Intrinsic and spontaneous neurogenesis in the postnatal slice culture of rat hippocampus. Eur J Neurosci (2004) 0.84
Role of the zinc fingers of HIV-1 nucleocapsid protein in maturation of genomic RNA. J Biochem (2003) 0.82
Reproduction of menstrual changes in transplanted human endometrial tissue in immunodeficient mice. Hum Reprod (2005) 0.82
Isolation and characterization of an infectious HIV type 1 molecular clone from a patient with primary infection. AIDS Res Hum Retroviruses (2002) 0.81
TNF-related apoptosis-inducing ligand (TRAIL) induces neuronal apoptosis in HIV-encephalopathy. J Med Dent Sci (2003) 0.81
Huwe1, a novel cellular interactor of Gag-Pol through integrase binding, negatively influences HIV-1 infectivity. Microbes Infect (2010) 0.80
A novel CD4-conjugated ultraviolet light-activated photocatalyst inactivates HIV-1 and SIV efficiently. J Med Virol (2008) 0.80
Th1/Th2 balance and HTLV-I proviral load in HAM/TSP patients treated with interferon-alpha. J Neuroimmunol (2004) 0.80
The hematopoietic cell-specific Rho GTPase inhibitor ARHGDIB/D4GDI limits HIV type 1 replication. AIDS Res Hum Retroviruses (2011) 0.80
Lineage analysis of newly generated neurons in organotypic culture of rat hippocampus. Neurosci Res (2010) 0.79
Role of nucleotide sequences in the V3 region in efficient replication of CCR5-utilizing human immunodeficiency virus type 1 in macrophages. Virology (2002) 0.78
Phylogenetic heterogeneity of new HTLV type 1 isolates from southern India in subgroup A. AIDS Res Hum Retroviruses (2005) 0.78
Improving the estimation of the death rate of infected cells from time course data during the acute phase of virus infections: application to acute HIV-1 infection in a humanized mouse model. Theor Biol Med Model (2014) 0.78
Efficient transduction of cytotoxic and anti-HIV-1 genes by a gene-regulatable lentiviral vector. Virus Genes (2009) 0.77
T cell-based functional cDNA library screening identified SEC14-like 1a carboxy-terminal domain as a negative regulator of human immunodeficiency virus replication. Vaccine (2010) 0.77
Human immunodeficiency virus type-1 vulnerates nascent neuronal cells. Microbiol Immunol (2008) 0.76
Small intestine CD4+ cell reduction and enteropathy in simian/human immunodeficiency virus KS661-infected rhesus macaques in the presence of low viral load. J Gen Virol (2009) 0.76
Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions. J Virol (2013) 0.76
Perspectives of Genome-Editing Technologies for HIV Therapy. Curr HIV Res (2016) 0.75
[HIV encephalopathy and neural stem cell virology]. No To Shinkei (2006) 0.75
Autonomous proliferation of HTLV-CD4+ T cell clones derived from human T cell leukemia virus type I (HTLV-I)-associated myelopathy patients. Microbiol Immunol (2007) 0.75
[Modulation of HIV replication by cellular factors]. Tanpakushitsu Kakusan Koso (2007) 0.75
[A new murine model of HIV-associated encephalopathy]. No To Shinkei (2004) 0.75
Correction: HIV-1 competition experiments in humanized mice show that APOBEC3H imposes selective pressure and promotes virus adaptation. PLoS Pathog (2017) 0.75
[Sputnik sweetheart-virophage]. Uirusu (2008) 0.75
[Molecular mechanism of HIV-1 replication]. Nihon Rinsho (2002) 0.75
[HIV encephalopathy]. Rinsho Shinkeigaku (2005) 0.75
Immunohistochemical localization of steroidogenic enzymes in human follicle following xenotransplantation of the human ovarian cortex into NOD-SCID mice. Mol Reprod Dev (2003) 0.75
Development of human Graafian follicles following transplantation of human ovarian tissue into NOD/SCID/gammac null mice. Am J Reprod Immunol (2008) 0.75